SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Fresenius Medical Care AG & Co. KGAA (FMS)

NEW YORK, Jan. 9, 2017

The investigation concerns whether Fresenius and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On January 7, 2017, Fresenius revealed that its U.S. unit had received subpoenas from federal prosecutors asking for information about its connection with the American Kidney Fund, a charity that assists patients pay for kidney dialysis.  Following this news, Fresenius stock has dropped as much as $3.09 per share, or 7.26%, to $39.46 on January 9, 2017.

If you are aware of any facts relating to this investigation, or purchased Fresenius shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/fms.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com